Oracle Corp Stock Price, News & Analysis

Oracle has partnered with the National Institutes of Health (NIH) to develop the CoVPN Volunteer Screening Registry, a cloud system to facilitate COVID-19 clinical trials. Within a week of launch, over 100,000 volunteers registered. This initiative aims to support clinical trial sites across the U.S. and internationally, focusing on inclusivity for high-risk communities. Oracle's efforts include previous systems like the Therapeutic Learning System, which has gathered 1.5 million patient updates. This collaboration enhances large-scale clinical trials needed for vaccine development.

The Lawrence J. Ellison Institute for Transformative Medicine and Oracle have pioneered a two-step predictive algorithm to enhance cancer diagnostics, specifically for breast cancer. This innovative technique uses under 1,000 annotated pathology slides to train the algorithm, achieving high diagnostic accuracy in classifying tumors' ER/PR/HER2 status. The method utilizes tissue 'fingerprints' to recognize tumor patterns, demonstrating accuracy metrics of 0.89 AUC (ER), 0.81 AUC (PR), and 0.79 AUC (HER2). This research, supported by Oracle Cloud technology, aims to improve diagnostic efficiency and access, potentially benefiting underserved regions.

Oracle has secured a Framework Agreement to provide secure cloud services to the Government of Canada. This agreement allows Canadian federal government customers to manage sensitive data on Oracle Cloud Infrastructure. The Canadian government is adopting a cloud-first strategy, enhancing its digital transformation efforts through Oracle's cloud services available in Toronto and Montreal. The partnership emphasizes Oracle's capabilities in machine learning, security, and autonomous database technology, meeting the compliance needs of public sector clients.

Oracle has launched the Oracle Dedicated Region Cloud@Customer, a fully-managed cloud region providing all second-generation cloud services, including Autonomous Database, directly to customer data centers. Starting at $500K monthly, this offering aims to meet the needs of highly regulated businesses by ensuring low latency, data residency compliance, and operational cost reduction. With over 50 services available on-premises, it caters to enterprises seeking a hybrid cloud architecture that merges public cloud capabilities with on-premises security and management.

Oracle announced the launch of Oracle Autonomous Database on Exadata Cloud@Customer, enhancing its cloud services by allowing organizations to run the latest database technology on-premises. This solution aims to simplify transitions to the cloud, reduce operational costs by up to 50%, and automate database management. With capabilities like elastic scaling and autonomous operations, it provides a scalable, high-performance database solution. Key customers, including Samsung SDS and NTT DoCoMo, have successfully implemented this service to improve efficiency and performance.

Oracle has announced that Nomura Research Institute (NRI) will implement the Oracle Dedicated Region Cloud@Customer to migrate its crucial business platform, primarily for the financial sector, to the cloud. This transition will allow NRI, which serves around 70% of capital markets firms in Japan, to utilize Oracle's comprehensive cloud services while maintaining strict control over their data in their own datacenter. Oracle aims to enhance its partnership with NRI, focusing on modernizing services for the financial industry and leveraging Oracle's cloud solutions to improve operational efficiency.

Oracle Health Sciences has launched the Clinical One Data Collection Cloud Service, which revolutionizes data collection in decentralized clinical trials. This platform integrates data from diverse sources including wearables and EHRs, enabling enhanced decision-making and efficiency in clinical research. According to participants, the service facilitates quicker study setups and mid-study adjustments. It is adaptable for various trial phases and supports ongoing studies like those for COVID-19 therapies. This initiative addresses the industry's need for lower-cost, efficient clinical trial solutions.

Oracle Corporation announced its Q4 and full-year results for fiscal 2020, reporting total revenues of $10.4 billion in Q4, down 6% year-over-year. Cloud services and license support revenues increased 1% YoY to $6.8 billion. FY2020 total revenues were $39.1 billion, flat year-over-year. GAAP net income for Q4 reached $3.1 billion, while FY2020 was $10.1 billion. Non-GAAP EPS for Q4 was $1.20, up 3% YoY. The board declared a quarterly cash dividend of $0.24 per share.